3 New Strong Buy Ratings from Top-Rated Analysts: 03/13/2026
Hello. These stocks are getting rave reviews from our Zen Ratings system:
- AnaptysBio (ANAB) — FDA milestone could unlock 55% upside potential
- Ross Stores (ROST) — Discount retailer expanding fast near 52-week highs
- Broadcom (AVGO) — AI infrastructure giant trading 17% off its highs
P.S. Want more trending stocks? Check out this video on 4 stocks with massive upside potential right now.
A note from our sponsors...
10 Stocks for Income and Triple-Digit Potential
If you're looking for income, stability, and upside, this is the list you want. Our Top 10 Best Stocks to Own in the Second Half of 2026 features elite dividend growers - companies that have historically boosted payouts while delivering market-beating gains. In the right market environment, these stocks can double, triple, even quintuple your annual dividend income over time. Combine that with post rate cut upside potential and you've got a rare opportunity for compounding gains on two fronts.
This report is free for a limited time - download it now before it disappears behind the paywall.
1. Anaptysbio (NASDAQ: ANAB)
AnaptysBio is a clinical-stage biotech on the verge of a major catalyst — the FDA has accepted its application for imsidolimab in generalized pustular psoriasis, Q4 earnings beat estimates, and a strategic business separation is in the works to unlock even more value.
Zen Rating: Strong Buy (A) — see full analysis
Recent Price: $62.10 — get current quote
Max 1-year forecast: $100.00
Why we're watching:
- Analyst support: Strong consensus with 5 Strong Buy ratings and 2 Buy ratings among 7 analysts covering the stock. See the ratings
- For example, Barclays researcher Etzer Darout (a top 2% rated analyst) recently maintained his Strong Buy rating with a $79 price target following positive momentum. An increase in market share is anticipated following new product launches with market entry planned for Q4.
- Wells Fargo analyst Derek Archila (top 2%) also maintains a Strong Buy rating with an $81 price target.
- Industry ranking context: ANAB is currently the 11th highest-rated stock in the Biotech industry, which has an Industry Rating of F.
- Zen Rating highlights: Strong Buy (A) stocks average +32.52%/yr — this is a high conviction stock among the thousands of stocks we track.
- Component Grades: The company earns a B grade for Value and Financials, indicating solid fundamental strength despite operating in a challenging biotech sector with an F-rated industry backdrop. See all 7 Zen Component Grades here
2. Ross Stores (NASDAQ: ROST)
Ross Stores is doubling down on growth — with 17 new locations announced this month, the off-price retail giant behind Ross Dress for Less and dd's DISCOUNTS is riding a wave of momentum, and Wall Street analysts are upgrading the stock as confidence in its competitive edge grows.
Zen Rating: Buy (B) — see full analysis
Recent Price: $211.75 — get current quote
Max 1-year forecast: $245.00
Why we're watching:
- Analyst support: Strong Street backing with 8 Strong Buy ratings, 3 Buy ratings, and 2 Hold ratings among 13 analysts tracking the stock. See the ratings
- Telsey Advisory Group's Dana Telsey (a top 3% rated analyst) recently upgraded Ross to Buy with a $240 price target, signaling increased conviction in the off-price retailer's trajectory.
- Barclays analyst Adrienne Yih (top 4%) holds a Strong Buy rating with a $242 price target, representing 13.68% upside potential.
- Industry ranking context: Ross ranks 3rd in the Apparel industry, which carries a strong A Industry Rating, positioning it among sector leaders.
- Zen Rating highlights: Buy (B) stocks average +19.88%/yr, putting ROST in a class of stocks that have historically trounced the S&P.
- Component Grades: Ross earns B grades for Sentiment, Safety, and Financials, with a solid 49.34% return on equity demonstrating efficient capital deployment and strong operational execution. See all 7 Zen Component Grades here
3. Broadcom (NASDAQ: AVGO)
Broadcom is trading nearly 18% off its highs — and that dip could be a gift. The semiconductor and software powerhouse just launched its first 400G/lane optical DSP for next-gen AI networks, cementing its role as a critical backbone of the AI infrastructure boom.
Zen Rating: Buy (B) — see full analysis
Recent Price: $335.92 — get current quote
Max 1-year forecast: $582.00
Why we're watching:
- Analyst support: Overwhelming bullish sentiment with 17 Strong Buy ratings, 5 Buy ratings, and just 2 Hold ratings among 24 analysts. See the ratings
- Morgan Stanley's Joseph Moore (a top 1% rated analyst) recently maintained his Strong Buy rating with a $470 price target, citing robust earnings and strong growth forecasts with the company well-positioned to leverage market opportunities.
- Truist Securities researcher William Stein (top 1%) holds the most bullish target at $545, representing 59.56% upside, expressing confidence in future profitability and sustained growth drivers with expansion to new sectors anticipated.
- Citigroup analyst Atif Malik (top 1%) maintains a Strong Buy with a $475 target, noting Broadcom remains a critical player in the tech supply chain with substantial growth expected in earnings and revenue.
- Nancy Pelosi is a notable AVGO investor — and in case you didn’t know, she’s got a GREAT track record. Check out more of her holdings here.
- Industry ranking context: Broadcom ranks 5th in the Semiconductor industry, which has a B Industry Rating, positioning it among the elite in a high-growth sector.
- Zen Rating highlights: Buy (B) rated stocks average +19.88%/yr — AVGO could even exceed this. Why? Several positive signs, like the fact that analysts project 49.06% earnings growth compared to 34.84% for the semiconductor industry and 36.16% market-wide.
- Component Grades: Broadcom ranks in the 80th percentile for Value, and the 85th percentile of stocks we track for Growth and Financials, demonstrating exceptional fundamental strength with 120.69% return on equity and 56.73% return on assets. See all 7 Zen Component Grades here
What to Do Next?
Want to get in touch? Email us at news@wallstreetzen.com.
Keep Reading
See All News
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.